Adv Hematol News Today

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

LACHEN, Switzerland, June 6, 2023 /PRNewswire/ -- Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 CongressNew

Asciminib final draft recommended by the National Institute for Health and Care Excellence (NICE) for use for treatment of adult patients with Philadelphia chromosome-positive chronic myeloid

Share this article Share this article LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www...

22 febbraio 2021 17:11 Fonte: Adnkronos #chimica-e-farmacia - LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProte...

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq in previously untreated patients with severe haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/...

Octapharma Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A Thursday, February 18, 2021 4:01PM IST (10:31AM GMT)   LACHEN, Switzerland:   Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading ...

Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10....

Share: Octapharma announced today a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which will be held virtually from February 3–5, 2021. The satellite symposium, A family journey with Nuwiq ®: Early treatment decisions for long-term health, will be chaired by Dr Robert F. Sidonio Jr. (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Childrens Healthcare of Atlanta, Emory Unive...